Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Department of Hepatology, The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China.
Dig Liver Dis. 2019 Aug;51(8):1172-1178. doi: 10.1016/j.dld.2019.01.011. Epub 2019 Jan 26.
The Albumin-Bilirubin (ALBI) score was developed to predict the long-term prognosis of hepatocellular carcinoma patients. We aimed to investigate the performance of ALBI for predicting severity and long-term prognosis of chronic hepatitis B-related liver cirrhosis (CHB-LC).
CHB-LC patients were enrolled from two medical centers between 2011 and 2017. The prognostic performance of ALBI was evaluated and compared with Child-Turcotte-Pugh (CTP), model of end-stage liver disease (MELD) and MELD integrating sodium (MELD-Na) scores.
This study enrolled 398 CHB-LC patients and patients were followed up for a median of 33.9 (IQR 21.6-48.8) months. The ALBI (HR: 3.151, 95% CI: 2.039-4.869,P < 0.001) was identified as an independent predictor of liver-related mortality. The receiver operating characteristic curves (ROCs) analysis revealed that ALBI score (0.756, 0.745, 0.739, 0.767 and 0.765) was superior to MELD score (P < 0.05) and comparable with CTP score (P > 0.05) for predicting 2-year, 3-year, 4-year, 5-year and global mortality. The AUROCs of ALBI score were significantly higher than MELD-Na score(P < 0.05) for predicting 2-year, 3-year and 5-year mortality. Patients with lower ALBI grade had a significantly lower mortality than patients with higher ALBI grade (P < 0.05).
ALBI score accurately predicts the severity and long-term prognosis of patients with CHB-LC. The prognostic performance of ALBI score was superior to MELD and MELD-Na score.
白蛋白-胆红素（ALBI）评分用于预测肝细胞癌患者的长期预后。我们旨在研究 ALBI 对预测乙型肝炎相关肝硬化（CHB-LC）严重程度和长期预后的作用。
本研究纳入了 2011 年至 2017 年期间来自两个医疗中心的 CHB-LC 患者。评估了 ALBI 的预后性能，并与 Child-Turcotte-Pugh（CTP）、终末期肝病模型（MELD）和 MELD 钠整合（MELD-Na）评分进行了比较。
本研究纳入了 398 例 CHB-LC 患者，中位随访时间为 33.9（IQR 21.6-48.8）个月。ALBI（HR：3.151，95%CI：2.039-4.869，P<0.001）被确定为肝相关死亡率的独立预测因子。受试者工作特征曲线（ROC）分析显示，ALBI 评分（0.756、0.745、0.739、0.767 和 0.765）在预测 2 年、3 年、4 年、5 年和总死亡率方面优于 MELD 评分（P<0.05），与 CTP 评分相当（P>0.05）。ALBI 评分的 AUC 显著高于 MELD-Na 评分（P<0.05），用于预测 2 年、3 年和 5 年死亡率。ALBI 分级较低的患者死亡率明显低于 ALBI 分级较高的患者（P<0.05）。
ALBI 评分能准确预测 CHB-LC 患者的严重程度和长期预后。ALBI 评分的预后性能优于 MELD 和 MELD-Na 评分。
